PO.MCB07.02 · 分子与细胞生物学
使用PaintScape™系统对ER+和HER2+乳腺癌细胞系中三维基因组结构进行原位直接单细胞可视化
In-situ direct single-cell visualization of 3D genome architecture in ER+ and HER2+ breast cancer cell lines using PaintScape TM system
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
乳腺癌(BC)高度异质,仅基于ER、PR和HER2表达的分类不能完全反映其临床多样性或治疗易感性。特别是,侵袭性的HER2阳性(HER2+)和雌激素受体阳性(ER+)亚型由复杂的基因组和细胞动力学驱动——包括上皮-间质转化(EMT)、染色体不稳定性和三维基因组重组——这些促成了转移、治疗耐药和不良预后。诸如WGS和Hi-C等批量研究揭示了BC亚型中的关键基因组特征,如局灶性扩增(例如HER2+ BC中的CCND1-HER2共扩增;ER+ BC中的20号染色体q臂改变)、A/B区室转换、TAD边界破坏以及相关的致癌重新布线。然而,这些方法仍属离体和基于批量的,掩盖了空间和细胞异质性,无法捕捉单个细胞内结构和功能相互作用的全貌,而这对于理解疾病进展至关重要。为克服这些局限,能够解析动态3D基因组变化的原位单细胞技术对于揭示耐药机制以及实现针对每个肿瘤细胞独特基因组图景量身定制的精准治疗至关重要。
在此,我们呈现PaintScape™系统,可对单个BC细胞中的3D基因组结构进行同步原位可视化。使用我们的OncoPaint™致癌通路面板,在ER+ MCF7和HER2+ HCC 1954细胞系中,跨所有染色体可视化了1,000多个与若干重要癌症通路(包括细胞周期与凋亡、转录调控与染色质结构)相关的靶标。我们识别了MCF7、HCC 1954和其他乳腺细胞系之间共有的以及细胞系特异性的独特3D基因组改变,并将这些改变与从患者样本推断的基因组重排模式相关联。在ER+ MCF7中,我们在单细胞和亚群体水平上识别了特定染色体臂(如20号染色体q臂)的拷贝增益/丢失分布、包括聚集断点区域在内的个别靶标、独特的ecDNA以及远端雌激素反应元件(DERE)。在HER2+ HCC 1954中,我们识别了8号染色体q臂的局灶性扩增,并直接可视化了MYC和CCND1等关键致癌基因的ecDNA扩增、重排和核定位。我们在MCF7和HCC 1954中同步原位展示了关键致癌区域的A/B区室转换和TAD边界破坏,显示出与细胞系间基因上调/下调的一致性。
PaintScape系统能够对单个细胞内的3D基因组进行同步原位绘图,揭示了BC亚型间与基因失调相关的结构差异,提供了基因组结构如何在疾病进展过程中影响细胞过程的整合视角。
查看英文原文 English abstract
Breast cancer (BC) is highly heterogeneous, and classification based on ER, PR, and HER2 expression alone does not fully capture its clinical diversity or therapeutic vulnerabilities. In particular, the aggressive HER2 positive (HER2+) and estrogen receptor positive (ER+) subtypes are driven by complex genomic and cellular dynamics-including epithelial to mesenchymal transition (EMT), chromosomal instability, and 3D genome reorganization that contribute to metastasis, therapy resistance, and poor prognosis. Bulk studies such as WGS and Hi-C have revealed key genomic features in BC sub-types such as focal amplifications (e.g. CCND1-HER2 co-amplification in HER2+ BC; Chr 20q alterations in ER+ BC), A/B compartment switching, TAD boundary disruptions and associated oncogenic rewiring. However, these approaches remain ex-situ and bulk-based obscuring the spatial and cellular heterogeneity and fail to capture the full spectrum of structural and functional interactions within individual cells which is critical to understanding disease progression. To overcome these limitations, in-situ single-cell technologies capable of resolving dynamic 3D genome changes are essential for uncovering resistance mechanisms and enabling precision therapies tailored to the unique genomic landscape of each tumor cell.
Here we present the PaintScape™ system enabling simultaneous in-situ visualization of the 3D genome structure in single BC cells. Over 1,000 targets relevant in several important cancer pathways including Cell Cycle and Apoptosis, Transcriptional Regulation and Chromatin Structure are visualized across all chromosomes using our OncoPaint™ Oncogenic Pathways Panel in ER+ MCF7 and HER2+ HCC 1954 cell lines. We identified common and cell line specific unique 3D genome alterations between MCF7, HCC 1954 and other breast cell lines, and relate these to patterns of genomic rearrangement inferred from patient samples. In ER+ MCF 7, we identified distributions in copy gain/loss of specific chromosome arms e.g. Chr 20q, individual targets including regions of clustered breakpoints, unique ecDNA and distal estrogen response elements (DEREs), at the single cell, and sub-population level. In HER2+ HCC 1954, we identified focal amplification of Chr 8q and directly visualized ecDNA amplification, rearrangement and nuclear localization of key oncogenes such as MYC and CCND1. We simultaneously show A/B compartment switching and TAD boundary disruption of key oncogenic regions in MCF7 and HCC 1954 in-situ, showing consistency with up/down regulation of genes between the cell lines.
The PaintScape system enables simultaneous in-situ 3D genome mapping within single cells revealing structural differences linked to gene dysregulation across BC sub-types, offering an integrated view of how genome architecture influences cellular processes during disease progression.
利益披露 Disclosure
H. Nguyen,
Bruker Spatial Genomics Employment, Stock Option.
S. Pribus, None..
Z. Ma, None.
D. King,
Bruker Spatial Genomics Employment, Stock Option.
J. Huynh,
Bruker Spatial Genomics Employment.
S. Tulu,
Bruker Spatial Genomics Employment, Stock Option.
M. Glazer,
Bruker Spatial Genomics Employment, Stock Option.
B. Smart,
Bruker Spatial Genomics Employment, Stock Option.
D. Castillo,
Bruker Spatial Genomics Employment, Stock Option.
K. Chung,
Bruker Spatial Genomics Employment, Stock Option.
S. Chattoraj,
Bruker Spatial Genomics Employment, Stock Option.
J. Dunne,
Bruker Spatial Genomics Employment, Stock Option.
D. Werner,
Bruker Spatial Genomics Employment, Stock Option.
C. Curtis, None.
M. Munch,
Bruker Spatial Genomics Employment, g., Board of Directors, non-salaried role), Stock, Stock Option.